A sealed reckoning of the four-peptide KLOW research record — KPV, GHK-Cu, BPC-157 and TB-500 weighed one vault-plate at a time, the component literature appraised on its merits and the missing blend evidence engraved as an empty reserve.
KLOW Reviews

CONSTITUENT ASSAY · FOUR BOLTS OF THE VAULT

Inside the KLOW stack: the four peptides

Four arms. Four separate literatures. One vial — and the honest accounting of what each arm brings to the door.

Read the research recordKLOW vs GLOW

In plain English

The KLOW stack is a research vial that holds four separate peptides co-dissolved at fixed amounts. It is important to understand — and this page exists to make it clear — that these four compounds do not merge into a single molecule in the vial. They are each distinct chemical entities, dissolved together for convenience of handling in research. The four-arm design reflects a logical rationale: target inflammation, matrix rebuilding, new blood-vessel growth, and cell migration all at once, since those are four different steps in tissue repair. But the KLOW peptide blend itself — all four together — has never been tested in a controlled study. What follows is a detailed account of each arm, its chemistry, its mechanism, and what the published evidence actually shows. KLOW peptide research for each component is summarized here in plain terms before the technical detail.

KPV — the anti-inflammatory arm

Sequence: Lys-Pro-Val (L-Lysine, L-Proline, L-Valine). Three amino acids. Molecular weight: 342.44 Da. CAS: 67727-97-3. Vial share: 10 mg of 80 mg total.

KPV is the C-terminal tripeptide of alpha-MSH — the last three residues of a 13-amino-acid hormone that modulates inflammation and melanin production. As a standalone fragment, its primary studied activity is anti-inflammatory: it enters the cells lining the gut via PepT1 (SLC15A1, the di/tripeptide transporter), and at nanomolar concentrations it blocks NF-kappaB from entering the cell nucleus, halting the transcription of inflammatory genes. It also reduces MAP-kinase activity and the secretion of TNF-alpha, IL-6, IL-1beta, and IL-8 in cell-culture experiments [3].

The PepT1 transport route is pharmacologically distinctive: PepT1 is upregulated in inflamed gut tissue and macrophages, so KPV uptake may be tissue-selective toward sites of active gut inflammation. Oral KPV at 100 micromolar in drinking water reduced severity in two murine colitis models. KPV Km at PepT1 is approximately 160 micromolar [3].

No controlled KPV monotherapy trial has reached approval; human data are limited to delivery pilots and an IBD-program lineage.

GHK-Cu — the matrix and copper arm

Sequence: Gly-His-Lys chelated 1:1 to a Cu(II) ion. Molecular weight: 402.92 Da. CAS: 89030-95-5. Vial share: 50 mg of 80 mg total (the mass-dominant component, ~62.5%).

GHK-Cu is a naturally occurring tripeptide first isolated from human plasma in 1973. It carries a copper(II) ion chelated (bound) to the histidine residue. Copper is the cofactor for lysyl oxidase (an enzyme that crosslinks collagen and elastin to give connective tissue its tensile strength); GHK-Cu delivers it in a bioavailable form.

Beyond copper delivery, GHK-Cu acts at the transcriptome level: the 2018 bioinformatic analysis found modulation of roughly 31.2% of human protein-coding genes at a 50%-or-greater change threshold, with the strongest gene-expression signals on extracellular-matrix remodeling, antioxidant defense, DNA repair, and the ubiquitin-proteasome system [5]. The 2015 clinical review documented improvements in skin laxity, clarity, fine lines, wrinkle depth, and density in placebo-controlled topical studies [4].

Endogenous plasma GHK declines from about 200 ng/mL at age 20 to about 80 ng/mL at age 60 — a documented age-associated gradient [4]. GHK-Cu dominates the KLOW vial by mass, and each molecule carries a copper atom, which makes the copper-loading caution for Wilson's disease (a genetic disorder of copper metabolism) relevant to this blend.

BPC-157 — the angiogenic arm

Sequence: GEPPPGKPADDAGLV (15 amino acids). Molecular weight: 1419.53 Da. CAS: 137525-51-0. Vial share: 10 mg of 80 mg total.

BPC-157 (Body Protection Compound 157, also known as PL 14736) is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein identified in human gastric juice. Originally developed as PL 14736 for inflammatory bowel disease research.

Its primary studied mechanism is VEGFR2/PI3K/Akt/eNOS angiogenic signaling: BPC-157 phosphorylates VEGFR2 (vascular endothelial growth factor receptor 2, the main switch for endothelial cells to form new blood vessels) and activates the downstream PI3K/Akt/eNOS cascade, promoting new capillary growth into injured tissue. It also modulates the nitric-oxide system in a manner that is partly resistant to L-NAME (a classical nitric-oxide synthase inhibitor), suggesting a nitric-oxide route distinct from the classical NOS pathway [12].

Rodent tissue-repair data: accelerated Achilles tendon healing across dose levels from 10 micrograms to 10 picograms per rat, with improved biomechanics, collagen organization, and tendocyte outgrowth [2]. Human data: one retrospective case series (87.5% knee-pain relief; n=16; uncontrolled) [8], one IV safety pilot (n=2; well tolerated at up to 20 mg) [6], one interstitial cystitis pilot (10 of 12 patients complete resolution; uncontrolled) [13].

FDA status: Category 2 on the 503A bulk-substances list, meaning it may not be compounded under Section 503A until additional safety and effectiveness information is submitted.

TB-500 — the cytoskeletal arm

Sequence: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (7 amino acids, N-terminally acetylated). Molecular weight: 889.02 Da. CAS: Not assigned for the fragment. Vial share: 10 mg of 80 mg total.

TB-500 corresponds to the LKKTET(Q) actin-binding motif of the 43-amino-acid native protein thymosin beta-4. Its mechanism centers on G-actin sequestration: the LKKTET hexapeptide core sequesters monomeric (globular) actin, which cells use as the building block for movement and cytoskeletal remodeling. By holding G-actin in reserve, the fragment modulates the pool available for leading-edge cytoskeletal dynamics — a step linked to cell migration and re-epithelialization.

The most foundational wound-healing data — the +42% re-epithelialization at 4 days and +61% at 7 days in rat full-thickness wound models [1] — are for full-length native thymosin beta-4, NOT for the TB-500 fragment. The fragment and the full protein share the actin-binding motif but differ in the integrin-linked kinase activation and epicardial progenitor mobilization activities established for the native protein.

Regulatory status: thymosin beta-4 (and by implication its fragment TB-500) is prohibited at all times under the WADA S2 list (peptide hormones and growth factors) [7]. The 2026 Sports Medicine review of unapproved musculoskeletal peptides notes that rigorous human safety data for TB-500/thymosin beta-4 are scarce [7].

The combination: why the vault has an empty drawer

The four arms above cover cytokine suppression (KPV), matrix synthesis and copper delivery (GHK-Cu), angiogenesis (BPC-157), and cell migration (TB-500/Tbeta4). The combination rationale is that these are four largely non-overlapping nodes of one tissue-repair cascade — sequential rather than redundant [10].

What the literature has never provided: a controlled study of the combination. No study has compared KLOW's four-peptide formulation to any monotherapy, any three-component subset, or placebo. All combination claims circulating in the research community are mechanistic extrapolations — not demonstrated outcomes.

A pharmacokinetic reality compounds the gap: the two tripeptides (KPV, GHK-Cu, MW ~342 and ~403 Da) are eliminated faster than BPC-157 (MW ~1420 Da), and TB-500 is a different molecular entity from the full-length thymosin beta-4 behind most large efficacy studies. A single reconstituted vial cannot hold all four at matched tissue exposures simultaneously.

This is the honest architecture. An evidence reckoning names both the deposits and the empty drawers.